1.29
-0.03(-2.27%)
Currency In USD
| Previous Close | 1.32 |
| Open | 1.3 |
| Day High | 1.33 |
| Day Low | 1.25 |
| 52-Week High | 17.83 |
| 52-Week Low | 1.19 |
| Volume | 555,851 |
| Average Volume | 1.16M |
| Market Cap | 68.04M |
| PE | -0.43 |
| EPS | -2.97 |
| Moving Average 50 Days | 1.59 |
| Moving Average 200 Days | 4.99 |
| Change | -0.03 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $43 as of February 05, 2025 at a share price of $1.29. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $91.49 as of February 05, 2025 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
GlobeNewswire Inc.
Jan 23, 2025 1:00 PM GMT
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
GlobeNewswire Inc.
Jan 22, 2025 9:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer an
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
GlobeNewswire Inc.
Jan 22, 2025 1:00 PM GMT
Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years